Latest Content

As peptides go mainstream, the FDA's shifting rules and a fractured state patchwork leave patients navigating a largely unregulated gray market.

Community oncologists cited prior authorization as a care barrier, even as AI adoption doubled in 2026, according to the Oncology Care Index.

A large propensity-matched study linked outpatient melatonin use to a small reduction in REM sleep in children evaluated for polysomnography.

Prior authorization and compounded drugs remain top obesity care access barriers, says NYU Langone's Holly Lofton, MD.

Panelists say IRA, Most Favored Nation rules and fragmented data are freezing value-based deals for durable one-time therapies.

Payers say NCCN guideline concordance sets a baseline for cancer coverage, but cost and formulary variation may still limit access.

At NASP's inSPire2026, covered entities and manufacturers debate 340B program reform, contract pharmacies, and the 2027 rebate model.

The FDA has approved belzutifan plus lenvatinib for advanced ccRCC after PD-1/PD-L1 therapy, expanding treatments for those with disease progression.

A 3-year registry found dupilumab controlled atopic dermatitis (AD) in most children, though those under 6 years were likelier to stop treatment.